Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D.
Villa D, et al.
Blood Adv. 2023 Aug 22;7(16):4576-4585. doi: 10.1182/bloodadvances.2023009804.
Blood Adv. 2023.
PMID: 37307169
Free PMC article.